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Abstract
The present pilot study investigated the effect of Teriparatide 1–34 rh-PTH (TPT) in young women diagnosed with anorexia 
nervosa (AN), and markedly compromised Bone Mineral Density (BMD). Patients were included who had (i) very low BMD 
(defined as Z-Score <  − 2.5 or T-Score <  − 2.5 if available) in at least one of the assessed localizations (lumbar spine L1–L4, 
total hip, femoral neck) without any previous fragility fracture; or (ii) low bone mineral density (defined as Z-Score <  − 1.5 
or T-Score <  − 1.5 if available) in at least one of the assessed localizations (lumbar spine L1–L4, total hip, femoral neck) and 
at least one previous fragility fracture. Ten patients with an age range of 21–33 were recruited and their bone outcome was 
assessed after 12, 18, and 24 months. After 24 months of TPT treatment, BMD improved by 13.5% in the spine, 5.0% in the 
femoral neck, and 4.0% in the hip. Radius cortical bone density (− 2.6%) and radius cortical thickness (− 6.4%) decreased 
significantly, while in tibia there was no significant decrease. Neither in radius nor in tibia a significant change in trabecular 
bone parameters occurred. During the treatment, the patients’ body weight did not increase significantly. Patients did not 
experience severe adverse events; only mild side effects were observed. Although these results emerged from a single-arm 
prospective study, it seems that AN patients with a severely compromised bone situation can benefit from TPT. Larger stud-
ies are needed to ascertain the effect of this promising substance.
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Introduction
Anorexia Nervosa (AN) is a psychiatric illness that affects 
about one percent of women, mostly at a young age [1]. The 
illness is difficult to treat and has an important tendency 
to become chronic [2]. Characteristic features of AN are 
self-induced starvation, weight loss and secondary problems 
associated with malnutrition; both physical and mental co-
morbid conditions are common [3]. Since four decades it is 
known that low bone mineral density (BMD) is a frequent 
complication in AN; young patients can indeed present a 
severe deterioration of BMD, and bone fracture is not unu-
sual [4].
The cause of the loss of bone mass and bone structure 
in AN is multifactorial; it is the result of hormonal adapta-
tions to the state of starvation. AN—as a form of chronic 
undernutrition—is characterized by hypogonadotropic 
hypogonadism, growth hormone resistance, and hypercor-
tisolemia [5].
Weight recovery and long term weight stabilization is the 
best treatment for low BMD in AN, coupled with a return of 
normal menses [6]; however, since only 50–60% of women 
with AN recover even two decades after their diagnosis [7, 
8], pharmacological treatment options are needed to reduce 
the chronic bone loss and the consequent increase in fracture 
risk.
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So far, there is no approved pharmacological treatment to 
target bone loss in AN [5]. Some pharmacological therapies 
have been investigated in short term studies in adults with 
AN, and have demonstrated some efficacy, e.g., bisphospho-
nates during 12 months [9], insulin-like growth factors (IGF-
1) together with oral contraceptives during 9 months [10], 
and transdermal estradiol replacement during 18 months 
[11], oral contraceptives, and dehydroepiandrosterone 
[12], or teriparatide (human parathyroid hormone) during 
6 months [13]. Teriparatide (TPT), the recombinant human 
1–34 parathyroid hormone, is a bone anabolic agent that is 
approved for the treatment of postmenopausal osteoporosis 
in women, hypogonadal osteoporosis in men, and gluco-
corticoid induced osteoporosis. Since TPTH has a potent 
anabolic effect on bone, this substance is of high interest 
in the treatment of low bone mass in AN. A randomized 
controlled trial reported an elevate increase in spine BMD 
(6–10%) after 6 months of treatment, compared to placebo in 
21 women (mean age 47 ± 1.7 years) with AN [13]. Unlike 
to this study, we decided to test this substance during a 
longer time period (24 months) in young women diagnosed 
with AN and bone deterioration. All patients had very low 
BMD in at least one of the assessed localizations (lumbar 
spine L1–L4, total hip, femoral neck) without any previous 
fragility fracture, or low BMD in at least one of the assessed 
localizations (lumbar spine L1–L4, total hip, femoral neck) 
and at least one previous fragility fracture.
BMD was measured with dual energy X-ray absorptiom-
etry (DXA). To capture also changes in the bone microarchi-
tecture due to TPT, High-Resolution peripheral quantitative 
Computed Tomography (HRpqCT) was also assessed. With 
the TPT treatment, we expected an increase in the BMD, and 
positive changes also in the HRpqCT parameters.
Methods
Inclusion Criteria
All patients were recruited in the in- and out-patients of the 
Eating Disorders Centre of the Department of Consultation-
Liaison Psychiatry and Psychosomatic Medicine of the Uni-
versity Hospital of Zurich. Female patients aged 18–35 years 
(closed epiphyses; patients younger than 22 years with 
closed epiphyses have to be confirmed with forearm X-ray) 
with anorexia nervosa since at least 12  months before 
inclusion.
Two bone conditions were analyzed to select the patients 
to be included in the study: (i) very low bone mineral den-
sity with or without previous fragility fracture. Very low 
bone mineral density is defined as a Z-Score at screening 
of lower than − 2.5 (or T-Score lower than 2.5 if available) 
in one or more of the assessed areas (L1–L4, total hip or 
femoral neck); (ii) low bone mineral density with at least 
one previous fragility fracture. Low bone mineral density 
is defined as Z-Score <  − 1.5 (or T-Score <  − 1.5 if avail-
able) in one or more of the assessed areas (L1–L4, total 
hip or femoral neck). All participants did agree to practice 
safe contraception during the overall period of the study and 
were capable of fully understanding the nature of the study. 
They did also sign the Informed Consent after being fully 
informed. All participants were also able to comply with the 
study protocol.
Exclusion Criteria
Exclusion criteria were: Metabolic bone diseases other 
than primary osteoporosis (including hyperparathyroidism, 
osteomalacia, Paget’s disease of bone), pre-existing hyper-
calcemia, severe renal impairment (GFR < 30 ml/min), prior 
external beam or implant radiation therapy to the skeleton, 
skeletal malignancies or bone metastases, any unknown ele-
vation of serum alkaline phosphatase, severe psychiatric dis-
eases other than AN, drug addiction, HIV positive patients, 
open epiphysis. Even contraindications to the class of drugs 
under study, e.g., known hypersensitivity or allergy to a class 
of drugs or the investigational product. Contraindications for 
ethical reasons, as determined by the investigator. Receiving 
or having received specific treatments against osteoporosis 
(e.g., bisphosphonates, zoledronate, denosumab) except cal-
cium and vitamin D. Previous therapy with calcium and/or 
vitamin D was allowed if on stable therapy for more than 
1 month. The hormone replacement therapy is allowed if a 
stable dose is given for more than 1 month before screening 
and even before the use of TPT.
Other exclusion criteria were pregnancy or a breast feed-
ing state, the intention to become pregnant during the course 
of the study, the lack of safe contraception (safe contracep-
tion was defined as follows: Female subjects of childbearing 
potential, using a medically reliable method of contracep-
tion for the entire study duration, such as oral, injectable, 
or implantable contraceptives, or intrauterine contraceptive 
devices, or using any other method considered sufficiently 
reliable by the investigator in individual cases; female sub-
jects who are surgically sterilized/hysterectomized).
Further exclusion conditions were known or suspected 
non-compliance, drug or alcohol abuse, the inability to fol-
low the procedures of the study (e.g., due to language prob-
lems, psychological disorders, dementia or a confusional 
state of the subject), participation in another study with any 
investigational drug taken within the 30 days preceding and 
during the present study; previous enrollment in the current 
study; enrollment of the investigator, his/her family mem-
bers, employees and other dependent people.
The evidence of severe hyper- or hypoparathy-
roidism (PTH > 800  ng/l or < 10  ng/l), hypocalcemia 
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(total calcium < 1.8 mmol/l) or hypercalcemia (total cal-
cium > 2.7 mmol/l) was also an exclusion criteria, as well as 
any other severe disease that in the opinion of the investiga-
tor could lead to metabolic bone disorder or influence frac-
ture rate (e.g., metastatic cancer, osteogenesis imperfecta, 
severe untreated hypo-/hyperthyroidism, other medications 
influencing bone metabolism).
Procedures and Assessments
The diagnosis of AN was made according to DSM IV-TR 
[14] at the Center for Eating Disorders, Department of Con-
sultation-Liaison Psychiatry and Psychosomatic Medicine, 
University Hospital of Zurich. All participants were exam-
ined by a rheumatologist (DF). Part of the standard rheuma-
tological assessment was a questionnaire on dietary calcium 
intake. Furthermore, participants completed a questionnaire 
including socio-demographic data, the history of eating dis-
order, (under)weight, menstruation, the use of medication, 
hormonal substitution or contraceptives, as well as the intake 
of vitamin, mineral, or calcium products. The questionnaire 
also included questions on the number of hours spent per 
week participating in sport. Out of 84 pre-screened patients 
71 were not eligible for the study mainly because of no low 
BMD (46%). Of the remaining 13 patients fulfilling inclu-
sion and exclusion criteria three withdrew consent before the 
beginning of the study. Two patients were non-compliant in 
administering TPT during the study after 6 and 18 months, 
respectively. One patient withdrew consent after 12 months. 
Seven patients concluded the study regularly.
Study participants self-administered 20 µg of TPT once 
daily sc during 24 months.
Anthropometric Measurements
Subjects were weighed on an electronic scale in underwear, 
and their height was measured with a stadiometer. The body 
mass index (BMI) was calculated using the formula weight 
in kilograms divided by height in meters squared.
Sociodemographic, Baseline Characteristics 
and Safety Laboratory Parameters
All patients were female and had a mean age of 25.4 years 
at the beginning of the study (see Table  1). The BMI 
ranged at the baseline from 13.6 to 18.8 kg/m2 (mean ± SD: 
15.6 ± 1.6), while the minimum lifetime BMI was 
12.9 ± 1.4  kg/m2. Eight patients (80%) had AN of the 
restricting type and two AN of the binge-purge type. The 
average duration of the disorder was 8.8 years. Two patients 
(20%) had a history of clinical significant fractures. The 
average age of menarche was 12.8 years. One patient had 
primary amenorrhea. 80% used sexual hormones with an 
average intake duration of 39 months (SD 41). All patients 
used calcium products and vitamin D, the intake of these 
supplements was not interrupted during the TPT treatment. 
No patients had osteoporosis specific treatment in the past 
like, e.g., bisphosphonates, or denosumab.
Safety laboratory parameters assessed were: Total cal-
cium, calcium correction for albumin, phosphate, creatinine, 
eGFR, vitamin D, FSH, estradiol, AP bone specific mass, 
intact parathormone.
Measurement of Bone Mineral Density, Body 
Composition and Bone Micro‑Architecture
All patients were examined with the following imaging 
methods:
Dual-energy X-ray absorptiometry (DXA) of the lumbar 
spine (L2–L4), the total proximal hip area and the femoral 
neck were performed using a Hologic QDR 4500 device 
(Hologic Corp., Inc., Waltham USA). DXA was used to 
measure the areal bone density of the lumbar spine (L2–L4), 
of the non-dominant femoral neck and of the total proximal 
hip area and it is expressed in grams per square centimeter. 
In addition, all values were expressed as T Scores, as abso-
lute numbers defined in 1994 by WHO (amount of standard 
deviations below or above the mean bone density value of 
Table 1  Patient characteristics (n = 10). Values presented as 
mean ± SD unless otherwise noted
a n = 9, one patient with primary amenorrhea
b Calcium 500 mg and vit D 800 UI
c 8 of 10 patients were under hormonal treatment at the beginning 
and during the trial. 4 of these 8 patients were treated with hormonal 
replacement therapy (3 × oral Estradiolvalerat/Norgestrel, 1 × trans-
dermal Estradiol/oral Dydrogesteron), 4 of the 8 patients took con-
traceptive drugs (1 × Ethinylestradiol/Gestoden, 2 × Ethinylestradiol/
Drospirenon, 1 × Ethinylestradiol/Cyproteronacetat).One patient of 
the study completers and one patient of the dropouts did not have hor-
monal treatment
Variable Value Range
Age, years 25.4 ± 4.4 21–33
Age at menarche, years 12.8 ± 1.7a 10–16
Age at AN onset 16.6 ± 2.7 13–21
Duration of the disorder, years 8.8 ± 4.4 4–17
Minimum lifetime BMI, kg/m2 12.9 ± 1.4 10.5–16.0
BMI at baseline, kg/m2 15.6 ± 1.6 13.6–18.8
Total physical activity, h/week 5.7 ± 3.1 0–8
History of fracture, % 20
Use of calciuim  productsb, % 100
Vitamin D  useb, % 100
Sexual hormone  usec, % 80
Smoking, % 20
Alcohol use, % 10
Hashish use, % 0
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young white Caucasian women at peak bone mass). The pre-
cision of the DXA measurement and the coefficient of varia-
tion (CV) at the level of the lumbar spine was 1%, at the hip 
1.5%, respectively. The least significant change (LSC at 95% 
confidence level) was 0.029 g/cm2 (CV% 3.04) at lumbar 
spine, 0.023 g/cm2 (CV% 2.71) at hip total, and 0.032 g/cm2 
(CV% 4.90) at femoral neck. DXA also allows to measure 
the body composition assessing percent of fat and lean mass 
(LM) including bone mineral content. The DXA measure-
ments were conducted in the Department of Rheumatology 
at University Hospital of Zurich.
High-resolution peripheral quantitative computed tomog-
raphy (HRpqCT) of the tibia and of the non-dominant 
forearm using multislice three-dimensional quantitative 
computer tomography (Scanco™ Medical, Bassersdorf, 
Switzerland). This method provides to achieve a number 
of parameters, which describe the microarchitecture of the 
bone tissue, and to obtain important information about the 
biomechanical properties of the bone. The measurement 
protocol included acquisition of a three-dimensional stack 
of 60 high-resolution CT slices at the most distal end of 
the radius using a total observation region of 10 mm. Slice 
thickness was 0.28 mm, pixel matrix 512 × 512 and pixel 
size 0.17 mm. To obtain cubic voxels, the consecutive cross-
sectional slices were measured in steps of 0.17 mm in the 
axial direction. Measuring parameters are defined as follows: 
D100, mean entire bone (cortical and trabecular) density of 
the ultradistal part of the radius in grams hydroxyapatite 
equivalence per  cm3 (grHA/cm3); Dcomp: bone density of 
the cortical part of the bone in grHA/cm3; C.Th.: absolute 
thickness of cortical bone in mm; Dtrab: density of the tra-
becular area of the bone in grHA/cm3; Dmeta: density of 
the subcortical area of the trabecular bone in grHA/cm3; 
Dinn: Density of the central part of the trabecular bone in 
grHA/cm3; Dinn and Dmeta together correspond to the total 
trabecular bone; BV/TV: relative bone volume as part of the 
total volume percent; Tb.N.: absolute number of trabecules 
per mm area; Tb.Th.: mean thickness of bone trabecules in 
mm; Tb.Sp.: mean separation distance between trabecules 
in mm. The precision of HRpqCT was < 1% [12, 13, 15, 16] 
. The HRpqCT were conducted at the Center for Age and 
Mobility of the Waid Hospital in Zurich.
The study was approved by the Cantonal Ethics Commit-
tee of Zurich (KEK-ZH-No. 2012-0297) and by the regula-
tory Authority Swissmedic (Reference No. 2013DR3141). 
The trial was also listed in ClinicalTrials.gov (NCT number: 
NCT01801397). All participants gave their written informed 
consent before being enrolled into the study.
Statistical Analysis
The primarily analyzed outcome of the study was defined as 
the absolute change of the BMD levels in the spine, the total 
hip and the femoral neck over the course of the study from 
baseline upon the end of the treatment period with TPT. To 
perform the intention-to-treat analyses (ITT), linear mixed 
model analyses including all participants (N = 10) were 
computed with time as a fixed factor. Model estimated mar-
ginal means of the outcome measures allowed to compare 
baseline (0 months) with later assessments (i.e., 12, 18 and 
24 months). Models were optimized by selecting a covari-
ance structure for repeated measures that produced the low-
est Akaike’s Information Criterion (AIC). For all calculated 
models, either a heterogeneous first-order autoregressive 
(ARH1), a first-order factor analytic (FA1), or a scaled iden-
tity (ID) covariance structure was appropriate. The threshold 
for statistical significance was set at p ≤ 0.05. Results are 
also given in % total change from baseline to the end of treat-
ment. Further linear mixed model analyses were performed 
with secondary outcome parameters. Since a change in BMI, 
percent fat, and lean mass respectively are potential con-
founding variables for changes in the outcome measures, we 
analyzed these variables in the course of time too. Addition-
ally, we computed linear mixed model analyses including 
these potential confounders as covariates. Each preceding 
analysis with significant results was repeated with all three 
confounders; however, including one confounder at a time. 
In order to complement the mixed model analyses, paired-
samples t-tests were calculated with primary and second-
ary outcome parameters in the per-protocol analysis (PP), 
completers; n = 7 comparing baseline with end of treatment 
values. BMD Z-scores of the completers are presented too. 
To avoid multiple testing, no further analyses with Z-scores 
were performed. Finally, using again paired-samples t-tests, 
changes within safety laboratory parameters were analyzed 
in per-protocol participants. For all analyses, we used IBM 
SPSS version 25 (IBM Corporation, Armonk, NY, USA).
Results
The primary endpoint consisted in testing the effect of TPT 
treatment during a period of 24 months in the lumbar spine, 
femoral neck and total hip BMD in patients with severe AN 
with an age range 21–33, very low bone mineral density and 
increased bone fragility. The results of the intention-to-treat 
analysis (ITT), (n = 10) are shown in Fig. 1. There was a 
significant increase in lumbar spine BMD after 12 months 
(mean difference = 0.051  g/cm2, SE = 0.015, p < 0.01), 
18 months (mean difference = 0.072 g/cm2, SE = 0.019, 
p < 0.01) and 24 months (mean difference = 0.090 g/cm2, 
SE = 0.019, p < 0.001, total change = 13.5%). For the fem-
oral neck BMD, the treatment showed its effect after 18 
(mean difference = 0.026 g/cm2, SE = 0.011, p < 0.05) and 
24 months (mean difference = 0.028 g/cm2, SE = 0.009, 
p < 0.05, total change = 5.0%). After 24 months of treatment, 
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the BMD level of the total hip area showed no significant 
increase (mean difference = 0.026  g/cm2, SE = 0.023, 
p = 0.33, total change = 4.0%).
Regarding the potential confounders, there was no sig-
nificant change in BMI from baseline to the end of treat-
ment (mean difference = 0.872 kg/m2, SE = 0.466, p = 0.11, 
total change = 5.6%) and in lean mass (mean differ-
ence = 0.927 kg, SE = 0.709, p = 0.23, total change = 2.8%), 
while an increase in percent fat occurred (mean differ-
ence = 3.74%, SE = 1.60, p < 0.05, total change = 19.6%, see 
Fig. 2). By repeating the mixed model analyses of the pri-
mary endpoints under inclusion of the confounders as covar-
iates, the significant results reported above were not essen-
tially altered. The increase in lumbar spine BMD turned out 
to be still significant at each time point (12 months: p < 0.05, 
18 months: p < 0.01, 24 months: p < 0.001). In addition, the 
model estimated increase in femoral neck BMD was still 
significant at 18 and 24 months (p < 0.05).
The evolution of the HRpqCT parameters on the 
radius bone is shown in Fig. 3. During the study period 
of 24  months, radius cortical bone density (mean dif-
ference = 21.8 mgHA/cm3, SE = 4.77, p < 0.01, total 
change =  − 2.6%) and radius cortical thickness (mean differ-
ence = 35.6 μm, SE = 10.8, p < 0.01, total change =  − 6.4%) 
decreased significantly. In radius, no significant change 
occurred neither in total bone density nor in trabecular bone 
density. By repeating these analyses under inclusion of the 
potential confounders (BMI, percent fat, and lean mass), 
these significant results were not altered, with the exception 
Fig. 1  Bone mineral density (g/
cm2) as measured with Dual-
energy X-ray absorptiometry 
(DXA) of lumbar spine, total 
hip and femoral neck in the 
course of time. Model estimated 
means (± std. error) at baseline, 
12, 18 and 24 months. Indica-
tors for significant changes 
compared to baseline (*p ≤ .05, 
**p ≤ .01, ***p ≤ .001)
Fig. 2  Body mass index (kg/
m2), percent fat, and lean mass 
incl. bone mineral content (kg) 
in the course of time. Model 
estimated means (± std. error) at 
baseline, 12, 18 and 24 months. 
Indicator for significant change 
compared to baseline (*p ≤ .05, 
**p ≤ .01, ***p ≤ .001)
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of the significance level of radius cortical thickness decrease 
(p < 0.05), when controlling for percent fat.
With respect to HRpqCT tibia parameters and bone 
parameters Fig. 4, no significant changes occurred from 
baseline to the end of the study, e.g., there was a small 
non-significant change in tibia total bone density at 
24 months (mean difference = 12.2 mgHA/cm3, SE = 10.0, 
p = 0.24, total change =  − 4.7%).
The results of the per-protocol analysis (PP), (n = 7) com-
paring the outcome parameters between baseline and end 
of treatment, are shown in Table 2. Basically, these results 
mirror the results of the intention-to treat analyses. At the 
individual level in 6 out of 7 patients a lumbar spine BMD 
Fig. 3  Radius bone parameters 
as measured with high-res-
olution peripheral quantita-
tive computed tomography 
(HRpqCT) in the course of 
time. Model estimated means 
(± std. error)1 at baseline, 12 
and 24 months. Indicators for 
significant changes compared 
to baseline (*p ≤ .05, **p ≤ .01, 
***p ≤ .001)
Fig. 4  Tibia bone parameters as 
measured with High-Resolution 
peripheral quantitative Com-
puted Tomography (HRpqCT) 
in the course of time. Model 
estimated means (± std. error)1 
at baseline, 12 and 24 months. 
No significant changes com-
pared to baseline (p > .05)
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improvement above LSC was measured, while this was the 
case in 3/7 patients at femoral neck and at total hip. In per-
protocol participants there was no significant increase in 
percent fat (t = − 1.83, df = 6, p = 0.12, change = 20.0%).
Analysis of the safety laboratory parameters of the per-
protocol analysis revealed non-significant changes in many 
parameters over the course of time (see Table 3). However, 
vitamin D level decreased from baseline to the end of treat-
ment (t = 3.26, df = 5, p < 0.05), as well as levels of parathy-
roid hormone (t = 2.53, df = 6, p < 0.05).
We did not observe any fracture in the patients during the 
overall study period.
Adverse Effects
TPT was generally well-tolerated by all study participants. 
Five patients reported nausea, two suffered from headache, 
two from dizziness. Rarely some patients reported pain in 
the thigh, or paresthesia of the arms. All this effects mostly 
presented in the first 2 weeks of the treatment, no patient 
discontinued the treatment due to side effects.
Table 2  Comparison of outcome parameters in the course of time for per-protocol participants (n = 7)
a Lean mass incl. bone mineral content
Time baseline, 
mean (SD)
24 months, mean (SD) Change t-test t (df) p (2-tailed) Partial η2
Body mass index (kg/m2) 15.6 (1.7) 16.6 (1.9) 6.4% − 1.96 (6) 0.10 0.39
Body composition: fat (%) 18.2 (5.0) 21.9 (4.9) 20.0% − 1.83 (6) 0.12 0.36
Body composition: lean  massa (kg) 33.4 (4.9) 34.7 (3.9) 4.0% − 1.66 (6) 0.15 0.31
Bone mineral density
 Lumbar spine
  g/cm2 0.660 (0.102) 0.749 (0.084) 13.5% − 3.79 (6)  < 0.01 0.71
  Z-score − 3.37 (0.98) − 2.63 (0.79)
 Femoral neck
  g/cm2 0.565 (0.055) 0.593 (0.049) 4.9% − 2.46 (6)  < 0.05 0.59
  Z-score − 2.53 (0.46) − 2.26 (0.39)
 Hip total
  g/cm2 0.651 (0.049) 0.676 (0.053) 3.8% − 1.70 (6) 0.14 0.32
  Z-score − 2.40 (0.39) − 2.17 (0.40)
Radius bone parameters
 Total bone density (mgHA/cm3) 253.6 (32.6) 245.5 (20.4) − 3.2% 1.36 (6) 0.22 0.23
 Cortical bone density (mgHA/cm3) 835.2 (58.9) 816.2 (65.6) − 2.3% 3.53 (6)  < 0.05 0.67
 Cortical thickness (μm) 565.7 (122.9) 534.3 (115.4) − 5.6% 6.18 (6)  < 0.001 0.86
 Trabecular bone density (mgHA/cm3) 134.6 (29.5) 132.4 (24.2) − 1.6% 0.34 (6) 0.74 0.02
 Meta trab. bone density (mgHA/cm3) 190.0 (29.0) 188.1 (22.7) − 1.0% 0.38 (6) 0.72 0.02
 Trabecular number (1/mm) 1.699 (0.301) 1.697 (0.360) − 0.1% 0.04 (6) 0.97 0.00
 Trabecular thickness (mm) 0.067 (0.018) 0.067 (0.017) 0.0% 0.00 (6) 1.00 0.00
 Trabecular separation (mm) 0.539 (0.116) 0.554 (0.162) 2.6% − 0.63 (6) 0.55 0.06
Tibia bone parameters
 Total bone density (mgHA/cm3) 261.4 (28.9) 250.0 (43.7) − 4.3% 0.96 (5) 0.38 0.16
 Cortical bone density (mgHA/cm3) 893.2 (37.3) 887.5 (48.8) − 0.6% 1.06 (5) 0.34 0.18
 Cortical thickness (μm) 888.3 (125.4) 883.3 (155.8) − 0.6% 0.21 (5) 0.84 0.01
 Trabecular bone density (mgHA/cm3) 154.1 (41.6) 141.7 (46.8) − 8.0% 1.10 (5) 0.32 0.19
 Meta trab. bone density (mgHA/cm3) 212.0 (39.0) 201.7 (43.5) − 4.9% 1.02 (5) 0.35 0.17
 Trabecular number (1/mm) 1.553 (0.374) 1.520 (0.456) − 2.1% 0.62 (5) 0.56 0.07
 Trabecular thickness (mm) 0.083 (0.018) 0.079 (0.017) − 5.4% 1.23 (5) 0.27 0.23
 Trabecular separation (mm) 0.595 (0.174) 0.643 (0.257) 7.9% − 0.99 (5) 0.37 0.17
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Discussion
The aim of this pilot study was to evaluate the effect of a 
24-month treatment with TPTH in a small group of AN 
patients with low BMD and increased bone fragility. The 
working hypothesis was that TPT could improve bone min-
eral density and the structure of young severely ill anorexic 
patients.
After 24 months of treatment with the anabolic agent 
TPT, the BMD increased significantly in the spine 13.5% 
and in the femoral neck 5.0% in young women with severe 
AN. This is a strong increase, in comparison with other sub-
stances [6]. Our results showed that TPT mediated a strong 
improvement of BMD in a group of young and severe under-
weight ill patients. It is noteworthy that adverse effects of the 
drug were minimal, which demonstrated that TPT represents 
a safe and effective treatment for AN patients with very low 
BMD. Important is also the fact that during the observed 2 
years no clinical significant fractures occurred.
Since normalization of the body weight has a positive 
effect on bone BMD [6], in this context, the development 
of the patients’ BMI during the study is important. During 
the course of the study, patients’ BMI did not increase sig-
nificantly, while the percent of body fat did. However, after 
controlling these potential confounders, our results were 
not altered unfavorably. Thus, the effect of TPT on BMD 
seems to be positive, regardless of a parallel body weight 
gain. In this context, it is cogitable that the intake of sexual 
hormones may have contributed to the positive results of 
the BMD.
To our knowledge, there is only one study that investi-
gates the effect of TPT in very young AN patients. Fazeli 
et  al. [13] administer the same substance during only 
6  months. Also this study showed a positive effect of 
BMD, but it was assessed in a remarkably older population 
(aged 47 years ± 2.7; our sample age 25 ± 4.4 years) than 
in our study. The two studies show other differences: the 
sample of Fazeli et al. was not severe underweight (mean 
BMI 17.6 ± 0.4 kg/m2), compared with our sample (mean 
BMI 15.6 ± 1.6 kg/m2). In addition, the results of the two 
studies are not identical. Fazeli et al. reported an increase 
of BMD only in the spine, and not in other localizations. 
We could find a very strong increase of the bone density 
of the spine; in addition,—and contrary to Fazeli et al. we 
could find also a significant increase of the bone density 
of the femoral neck. This result underlines the importance 
of a longer duration of the TPT treatment than 6 months 
(24 months), and have to be verified in larger studies. Since 
our sample was younger, it is also possible that the bone 
regeneration potential at a younger age is better than in pre-
menopausal women, like in the study of Fazeli et al. As far 
as we know, this is the first study that analyzes the effect of 
TPT with HRpqCT. Regarding the HRpqCT measurement 
of the bone microarchitecture of the radius, we could find an 
interesting reduction in the cortical thickness after 2 years, 
while the trabecular bone density (trabecular number and 
trabecular thickness) seems to remain constant. Remarkably 
different are the results of the tibia, indeed the bone archi-
tecture under TPT-therapy seems to be spared from signifi-
cant negative changes when we do not consider the cortical 
thickness which becomes slightly thinner, and the trabecular 
number which decreases slightly. The lack of amelioration 
of the HRpqCT parameters of the bone microarchitecture 
under TPT at the end of the treatment underlines the well-
known difficulty of regeneration of the peripheral bone in 
AN [17], so that in these patients a stabilization of bone 
parameters—a non-deterioration—could be interpreted as 
a positive result.
Our results (and the study results of Fazeli et al.) could 
suggest that the positive effect of TPT would be related more 
to the proximal bone and less to the peripheral bone.
The differences of the bone microarchitecture param-
eters of the two peripheral bones (radius and tibia) may in 
this sample—AN patients move willingly until becoming 
Table 3  Comparison of safety laboratory parameters in the course of time for per-protocol participants (n = 7)
Time baseline, 
mean (SD)
24 months, mean (SD) Change t-test t (df) p (2-tailed) Partial η2
Calcium, total (mmol/l) 2.40 (0.09) 2.45 (0.08) 2.2% − 0.97 (6) 0.37 0.14
Calcium albumin corr. (mmol/l) 2.25 (0.06) 2.29 (0.06) 1.8% − 0.93 (6) 0.39 0.13
Phosphate (mmol/l) 1.15 (0.16) 1.12 (0.08) − 2.7% 0.61 (5) 0.57 0.07
Creatinine (μmol/l) 58.1 (12.3) 60.6 (10.5) 4.2% − 0.73 (6) 0.49 0.08
eGFR (crea) (ml/min) 119.7 (15.0) 116.7 (14.0) − 2.5% 1.04 (6) 0.34 0.15
Vitamine D (μg/l) 42.7 (12.4) 34.5 (7.5) − 19.2% 3.26 (5)  < 0.05 0.68
FSH (IE/l) 1.84 (4.19) 1.81 (2.26) − 1.7% 0.03 (5) 0.98 0.00
Estradiol (pmol/l) 98.6 (150.9) 98.1 (106.8) − 0.4% 0.01 (6) 1.00 0.00
Bone specific alkaline phosphatase (μg/l) 8.30 (2.35) 13.20 (7.80) 59.0% − 1.53 (4) 0.20 0.37
Parathyroid hormone, intact (ng/l) 41.9 (11.9) 24.2 (10.7) − 42.2% 2.53 (6)  < 0.05 0.52
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hyperkinetic—be explained by a different exposure to 
the weight-bearing activity; in effect, tibia is much more 
exposed to repetitive weight-bearing activity than radius 
[18].
Unfortunately, in the present prospective study, we did 
not have a comparison (placebo) group. Several studies 
underline the negative course of the BMD in AN patients 
with lack of weight gain [6]. As this was an uncontrolled, 
one-arm pilot study, our results are limited to observations 
occurring in the whole group of participants over time. How-
ever, it can be assumed that this patient-group—with nega-
tive weight course—would not have had any positive bones 
course without pharmacological intervention. Regrettably is 
the reduction of the sample (three patients) during the study, 
however dropouts and reduced compliance are well-known 
in severe AN patients.
It is an important question if there will be a BMD loss 
after stopping TPT treatment in this young sample. Because 
a subsequent measurement after 2 years of treatment was not 
undertaken in this study, this is an issue for future research.
Low BMD is a very common medical comorbidity asso-
ciated with AN. Notably, bone loss is associated with an 
increased risk of fracture, and with this a low quality of life.
Conclusion
AN is an illness which is difficult to treat, with patients 
often showing a chronical course. The starvation state leads 
to changes in many hormonal systems and can lead to low 
BMD which is an important negative consequence of AN. 
The therapeutic possibilities against low BMD and increased 
bone fragility are limited. TPT treatment over 24 months 
might be a viable and safe option to treat severe young 
patients with little chances to gain weight. Larger controlled 
studies should be conducted to better test the efficacy and 
tolerance of this substance.
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